HCW Biologics (HCWB) Stock Price, News & Analysis

Company Overview

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Key Stats

• Today's Range: $6.96 to $7.44
• 50-Day Range: $6.90 to $14.60
• 52-Week Range: $6.36 to $100.80
• Volume: 14,543 shs
• Average Volume: 98,442 shs
• Market Capitalization: $8.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HCWB Stock Analysis - Frequently Asked Questions

How have HCWB shares performed this year?

HCW Biologics' stock was trading at $17.8440 at the start of the year. Since then, HCWB stock has decreased by 59.9% and is now trading at $7.15.
View the best growth stocks for 2025 here.

How were HCW Biologics' earnings last quarter?

HCW Biologics Inc. (NASDAQ:HCWB) released its quarterly earnings data on Friday, March, 28th. The company reported ($3.20) earnings per share for the quarter. The firm earned $0.40 million during the quarter. HCW Biologics had a negative net margin of 1,067.82% and a negative trailing twelve-month return on equity of 2,516.84%.

When did HCW Biologics' stock split?

HCW Biologics's stock reverse split before market open on Friday, April 11th 2025. The 1-40 reverse split was announced on Tuesday, April 1st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did HCW Biologics IPO?

HCW Biologics (HCWB) raised $45 million in an initial public offering on Tuesday, July 20th 2021. The company issued 5,600,000 shares at $8.00 per share. EF Hutton served as the underwriter for the IPO and Revere Securities was co-manager.

How do I buy shares of HCW Biologics?

Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HCW Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HCW Biologics investors own include Jiuzi (JZXN), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Kiora Pharmaceuticals (KPRX), Rallybio (RLYB), Adial Pharmaceuticals (ADIL) and Aridis Pharmaceuticals (ARDS).

Company Calendar

• Last Earnings: 3/28/2025
• Today: 5/08/2025
• Next Earnings (Estimated): 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HCWB
• CIK: 1828673
• Web: www.hcwbiologics.com
• Phone: 954-842-2024
• Fax: 954-842-2037
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($31.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-24,990,000.00
• Net Margins: -1,067.82%
• Pretax Margin: -1,067.79%
• Return on Equity: -2,516.84%
• Return on Assets: -132.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $2.57 million
• Price / Sales: 3.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 19.32

Miscellaneous

• Outstanding Shares: 1,123,000
• Free Float: 22,315,000
• Market Cap: $8.03 million
• Optionable: Not Optionable
• Beta: 0.85